logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Gilead Biologics, Inc.


USPTO Granted Patents = 16



Forward Citations = 120

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Victoria Smith (13 out of 312 patents)

silverMedal Scott Alan McCauley (13 out of 19 patents)

bronzeMedal Alison Kay Holzer (7 out of 7 patents)

4.  Hector Rodriguez (6 out of 10 patents)

5.  Carlos Aurelio Garcia (6 out of 6 patents)

6.  Scott Ogg (5 out of 6 patents)

7.  Peter Van Vlasselaer (5 out of 19 patents)

8.  Vivian E Barry (5 out of 5 patents)

9.  Miho Oyasu (5 out of 5 patents)

10.  Donna Hiroko Tokuoka Biermann (5 out of 5 patents)

11.  Derek Marshall (5 out of 8 patents)

12.  Maria Vaysberg (3 out of 4 patents)

13.  Michael J Hawkins (1 out of 3 patents)

14.  Joanne I Adamkewicz (1 out of 1 patent)

15.  Zung Thai (1 out of 1 patent)


16 patents:

1. 10800857 - Antibodies to matrix metalloproteinase 9 (2020-10-13),
2. 10494443 - LOX and LOXL2 inhibitors and uses thereof (2019-12-03),
3. 9732156 - Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9 (2017-08-15),
4. 9550836 - Method of detecting human matrix metalloproteinase 9 using antibodies (2017-01-24),
5. 9289447 - Chemotherapeutic methods and compositions (2016-03-22),
6. 9260532 - Antibodies to matrix metalloproteinase 9 (2016-02-16),
7. 9176139 - LOX and LOXL2 inhibitors and uses thereof (2015-11-03),
8. 9107935 - Chemotherapeutic methods and compositions (2015-08-18),
9. 8927700 - Catalytic domains from lysyl oxidase and LOXL2 (2015-01-06),
10. 8680246 - Antibodies that bind to lysyl oxidase-like 2 (LOXL2) (2014-03-25),
11. 8679485 - Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis (2014-03-25),
12. 8658167 - Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis (2014-02-25),
13. 8512990 - Catalytic domains from lysyl oxidase and LOXL2 (2013-08-20),
14. 8501916 - Antibodies to matrix metalloproteinase 9 (2013-08-06),
15. 8461303 - LOX and LOXL2 inhibitors and uses thereof (2013-06-11),
Gilead Biologics, Inc. is a leading biopharmaceutical company focused on the research, development, and commercialization of innovative therapies to address unmet medical needs. With a strong commitment to science and patient care, Gilead strives to improve the lives of people worldwide suffering from challenging diseases.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

16 Patents

#31 in Foster City, CA

#4,631 in California

#19,309 in US

#36,677 in the World

...
Foster City, CA, United States of America

Gilead Biologics, Inc.

Forward Citations = 120

15 inventors:

goldMedal Victoria Smith (13 out of 312 patents)

silverMedal Scott Alan McCauley (13 out of 19 patents)

bronzeMedal Alison Kay Holzer (7 out of 7 patents)

4.  Hector Rodriguez (6 out of 10 patents)

5.  Carlos Aurelio Garcia (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com
Loading…